On April 23, 2026, the U.S. Department of Justice reclassified certain marijuana products to Schedule III under the Controlled Substances Act. This change specifically covers FDA-approved cannabis medicines and state-regulated medical cannabis programs; it does not federally legalize recreational use. Employers should review policies and practices now that lawful medical cannabis use no longer fits the prior categorical label of “illegal drug use.”
What changed – Date: April 23, 2026. The DOJ moved specified marijuana products from Schedule I to Schedule III. Schedule III signals lower federal control and recognizes medical use for covered products. – Scope: The reclassification applies to FDA-approved marijuana drugs and to state-regulated medical cannabis in the categories specified by the DOJ. The move does not alter state law or automatically legalize recreational cannabis at the federal level. – Safety-sensitive roles: Rules from the U.S. Department of Transportation (DOT) for pilots, truck drivers, and other safety-sensitive positions remain in force and unchanged by this DOJ action.
Why employers must change course – Legal status shift: Previously, employer policies could treat all marijuana use as illegal drug use and deny accommodation requests on that basis. With the DOJ recognizing certain medical uses as lawful, employers face new ADA obligations when employees present qualifying medical use. – ADA interaction: Employers must now evaluate accommodation requests for employees who lawfully use medical cannabis and may need to engage in the ADA interactive process for qualified individuals with disabilities. – Testing and proof: A positive THC test no longer automatically signals unlawful use. Employers will need clearer proof standards to connect test results to job impairment or on-the-job policy violations.
Practical steps for employers (concrete actions) 1) Update written policies within 30–90 days. Change language that treats any cannabis use as per se illegal. Instead, state that on-duty impairment and possession during work hours remain prohibited, and explain how medical cannabis disclosures will be handled. 2) Train supervisors (within 60 days). Teach supervisors how to document observable performance or safety issues, how to report suspected impairment, and when to remove an employee from safety-sensitive duties pending assessment. 3) Revise testing protocols. Shift from relying solely on urine THC metabolites to a combination of approaches: impairment observation, job performance metrics, and, where appropriate, corroborating tests. Note that THC metabolites can remain detectable in urine for days to weeks (often up to 30 days in chronic users), so a positive test does not prove current impairment. 4) Implement ADA process steps. When an employee asserts a qualifying medical cannabis use, promptly: (a) verify whether the employee is a qualified individual with a disability, (b) request any necessary medical documentation consistent with ADA rules, and (c) consider reasonable accommodations such as schedule adjustments, temporary reassignment away from safety-sensitive duties, or unpaid leave when necessary and appropriate. 5) Maintain and document zero-tolerance for on-the-job impairment. Employers retain the right to prohibit being impaired at work and can take disciplinary action for impairment that endangers others or disrupts essential job functions. 6) Consult counsel for state conflicts. State medical cannabis laws differ. Where state rules grant broader employee protections, employers must reconcile state requirements with updated federal treatment and workplace safety obligations. Obtain legal counsel before making final policy changes.
Testing, impairment assessment, and evidence – Testing limits: Standard urine or blood tests detect THC metabolites, which do not reliably indicate current impairment. Use observation-based impairment assessments and job-performance data for disciplinary decisions. – Alternative approaches: Consider oral fluid testing (shorter detection window) or validated impairment evaluation protocols for safety-sensitive incidents. Pair any testing result with documented behavior and objective performance measures before taking adverse action.
Safety-sensitive and DOT-covered roles – No DOT change: DOT-regulated safety rules remain applicable. Employers should continue to follow DOT drug and alcohol regulations for covered employees without alteration. – Reassignments: For non-DOT safety-sensitive roles, employers can require reassignment or temporary removal from safety-sensitive duties while engaging the ADA process and assessing reasonable accommodations.
Risks and compliance priorities – Litigation risk: Treating medical cannabis use as automatically disqualifying may expose employers to ADA claims. Conversely, allowing on-the-job impairment risks workplace safety and liability. – Documentation: Record each step—policy updates, accommodation requests, interactive process notes, impairment observations, and decisions. Well-documented, consistent handling of cases reduces legal exposure.
Next steps and resources – Immediate review: Human resources and legal teams should audit drug policies and employee handbooks within 30 days. – Training schedule: Roll out supervisor and HR training within 60 days, with refresher sessions annually. – Expert guidance: Consult employment counsel experienced in ADA and state cannabis laws for tailored policy drafts. Miller Canfield has published a full legal analysis of the DOJ action; the Michigan Chamber of Commerce also summarized implications for employers.
Bottom line The DOJ reclassification of certain marijuana products to Schedule III changes how employers must treat lawful medical cannabis use. Employers must balance employee disability protections under the ADA with workplace safety requirements. Concrete steps—policy revision, supervisor training, revised testing protocols, and careful documentation—will help companies comply with federal and state rules while protecting workplace safety.
